Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study

Authors: Andritsos, Leslie A. ^{a, ⁎}, McBride, Ali ^b, Tang, Derek ^b, Barghout, Victoria ^c, Zanardo, Enrico ^d, Song, Rui ^e, Huynh, Lynn ^e, Yenikomshian, Mihran ^e, Makinde, Adeola Y. ^b, Hughes, Christina ^b, Hanna, Kirollos S. ^f, Patel, Kashyap ^g

Source: In Leukemia Research January 2025 148

Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents

Authors: Garcia-Manero, Guillermo, Matsuno, Rayna K., McBride, Ali, Mohammed, Hina, Idryo, Danny, Broome, Ronda, Herriman, Autumn, Johnson, Tiffany, Wilkinson, Kristiana, Schrag, Andrew, Johanson, Colden, Izano, Monika, Makinde, Adeola, Mukherjee, Sudipto

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24(9):e283-e292

Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes

Authors: Mascarenhas, John, Harrison, Claire, Schuler, Tammy A., Liassou, Djibril, Garretson, Marné, Miller, Taavy A., Mahadevan, Sankar, McBride, Ali, Tang, Derek, DeGutis, Irene S., Abraham, Pranav, Kish, Jonathan, Feinberg, Bruce A., Gerds, Aaron T.

Source: In Clinical Lymphoma, Myeloma and Leukemia February 2024 24(2):122-132

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Authors: McBride Ali, Westervelt Peter

Source: Journal of Hematology & Oncology, Vol 5, Iss 1, p 75 (2012)

Subject Terms: Acute renal failure, Allopurinol, Adverse events, Hematologic malignancies, Management, Prophylactic therapy, Solid tumors, Tumor lysis syndrome (TLS), Rasburicase, Uric acid, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.jhoonline.org/content/5/1/75; https://doaj.org/toc/1756-8722

Access URL: https://doaj.org/article/7a1bbe33e19048c289d4bb807e1855cb

Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database

Authors: Brunner, Andrew M., Huggar, David, Copher, Ronda, Zhou, Zheng-Yi, Zichlin, Miriam L., Anderson, Annika, Downes, Nathaniel, McBride, Ali

Source: In Leukemia Research September 2023 132

Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation

Authors: Halder, Ritika, Brucks, Eric, Cheng, Ce, Saboda, Kathylynn, Babiker, Hani M., Mcbride, Ali, Recio-Boiles, Alejandro

Source: In Thrombosis Update December 2022 9

Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia

Authors: Klink, Andrew J., Gajra, Ajeet, Knoth, Russell L., Marshall, Landon, Hou, Ying, McBride, Ali, Copher, Ronda

Source: In Leukemia Research November 2022 122

Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia

Authors: Alrawashdh, Neda, McBride, Ali, Erstad, Brian, Sweasy, Joann, Persky, Daniel O., Abraham, Ivo

Source: In Value in Health October 2022 25(10):1685-1695

Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study

Authors: McBride, Ali ^*, Daniel, Shoshana, Driessen, Maurice T., Szende, Agota, Choudhry, Azhar, Tian, Marc, Ariely, Rinat, Thompson, Stephen

Source: In Leukemia Research December 2021 111

Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves

Authors: Alrawashdh, Neda, Persky, Daniel O, McBride, Ali, Sweasy, Joann, Erstad, Brian, Abraham, Ivo

Source: In Clinical Lymphoma, Myeloma and Leukemia November 2021 21(11):e820-e831

Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma

Authors: McBride, Ali, MacDonald, Karen, Abraham, Ivo ^*

Source: In Leukemia Research July 2021 106

Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblast Leukemia: A Systematic Review

Authors: Warraich, Zabih, Tenneti, Pavan, Thai, Theresa, Hubben, Anne, Amin, Hina, McBride, Ali, Warraich, Sami, Hannan, Abdul, Warraich, Faiza, Majhail, Navneet, Kalaycio, Matt, Anwer, Faiz

Source: In Biology of Blood and Marrow Transplantation March 2020 26(3):e55-e64

Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients

Authors: Majeed, Aneela, Harris, Zoey, Brucks, Eric, Hinchman, Alyssa, Farooqui, Arafat Ali, Tariq, Muhammad Junaid, Tamizhmani, Kavin, Riaz, Irbaz bin, McBride, Ali, Latif, Azka, Kapoor, Vikas, Iftikhar, Raheel, Mossad, Sherif, Anwer, Faiz

Source: In Biology of Blood and Marrow Transplantation February 2020 26(2):e38-e50

Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis

Authors: Almutairi, Abdulaali R., Alkhatib, Nimer, Martin, Jennifer, Babiker, Hani M., Garland, Linda L., McBride, Ali, Abraham, Ivo ^*

Source: In Critical Reviews in Oncology / Hematology October 2019 142:16-25

Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization

Authors: Andritsos, Leslie A., Huang, Ying, Abraham, Ivo, Huff, Keith, Scrape, Scott R., Fan, Tao, Alkhatib, Nimer, Hofmeister, Craig C., Drea, Edward, McBride, Ali

Source: In Leukemia Research October 2019 85

Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma

Authors: Anwer, Faiz, Gee, Kevin Mathew, Iftikhar, Ahmad, Baig, Mirza, Russ, Atlantis Dawn, Saeed, Sabina, Zar, Muhammad Abu, Razzaq, Faryal, Carew, Jennifer, Nawrocki, Steffan, Al-Kateb, Hussam, Cavalcante Parr, Nadia Nunes, McBride, Ali, Valent, Jason, Samaras, Christy

Source: In Clinical Lymphoma, Myeloma and Leukemia July 2019 19(7):397-405

Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction

Authors: Fraz, Muhammad Asad, Warraich, Faiza Hassan, Warraich, Sami Ullah, Tariq, Muhammad Junaid, Warraich, Zabih, Khan, Ali Younas, Usman, Muhammad, Ijaz, Awais, Tenneti, Pavan, Mushtaq, Adeela, Akbar, Faisal, Shahid, Zaina, Ali, Zeeshan, Fazeel, Hafiz Muhammad, Rodriguez, Cesar, Nasar, Aboo, McBride, Ali, Anwer, Faiz

Source: In Critical Reviews in Oncology / Hematology May 2019 137:18-26

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation

Authors: Ijaz, Awais, Khan, Ali Younas, Malik, Saad Ullah, Faridi, Warda, Fraz, Muhammad Asad, Usman, Muhammad, Tariq, Muhammad Junaid, Durer, Seren, Durer, Ceren, Russ, Atlantis, Parr, Nadia Nunes Cavalcante, Baig, Zeeshan, Sagar, FNU, Ali, Zeeshan, McBride, Ali, Anwer, Faiz

Source: In Biology of Blood and Marrow Transplantation January 2019 25(1):94-99

Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system

Authors: Babiker, Hani M, McBride, Ali, Newton, Michael, Boehmer, Leigh M., Drucker, Adrienne Goeller, Gowan, Mollie, Cassagnol, Manouchkathe, Camenisch, Todd D., Anwer, Faiz, Hollands, James M.

Source: In Critical Reviews in Oncology / Hematology June 2018 126:186-200

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review

Authors: Mushtaq, Adeela, Kapoor, Vikas, Latif, Azka, Iftikhar, Ahmad, Zahid, Umar, McBride, Ali, Abraham, Ivo, Riaz, Irbaz Bin, Anwer, Faiz

Source: In Critical Reviews in Oncology / Hematology May 2018 125:1-11